Article
N-nitrosamine impurity risk assessment in pharmaceuticals: Utilizing In vivo mutation relative potency comparison to establish an acceptable intake for NTTP.
Regulatory toxicology and pharmacology : RTP - 1 Sept 2024
Powley Mark W, Sobol Zhanna, Johnson George E, Clark Robert W, Dalby Stephen M, Ykoruk Bridget A, Galijatovic-Idrizbegovic Alema, Mowery Mark D, Escobar Patricia A
Abstract excerpt
The finding of N-nitrosodiethylamine (NDEA) and N-nitrosodimethylamine (NDMA) in marketed drugs has led to implementation of risk assessment processes intended to limit exposures to the entire class of N-nitrosamines. A critical component of the risk assessment process is establishing exposure limits that are protective of human health. One approach to establishing exposure limits for novel N-nitrosamines is to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
